Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease

First Posted Date
2019-07-01
Last Posted Date
2020-05-21
Lead Sponsor
Green Cross Corporation
Target Recruit Count
45
Registration Number
NCT04003844
Locations
🇰🇷

Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of

🇰🇷

Kyung Hee University Medical Center, Seoul, Korea, Republic of

🇰🇷

The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of

and more 4 locations

Platelet Sub-study of the TWILIGHT Trial

First Posted Date
2019-06-28
Last Posted Date
2020-02-26
Lead Sponsor
Juan Badimon
Target Recruit Count
40
Registration Number
NCT04001374
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention

First Posted Date
2019-05-23
Last Posted Date
2023-08-16
Lead Sponsor
University of Zurich
Target Recruit Count
620
Registration Number
NCT03961334
Locations
🇬🇷

Attikon University Hospital, Athens, Greece

🇪🇸

Hospital Universitario Virgen Macarena, Sevilla, Spain

🇨🇭

University Hospital of Basel, Basel, Switzerland

and more 11 locations

Assessment of Direct Biomarkers of Aspirin Action to Develop a Precision Chemoprevention Therapy of Colorectal Cancer

Phase 2
Conditions
Interventions
First Posted Date
2019-05-21
Last Posted Date
2019-05-21
Lead Sponsor
Instituto de Investigación Sanitaria Aragón
Target Recruit Count
60
Registration Number
NCT03957902
Locations
🇪🇸

Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain

Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM

First Posted Date
2019-04-25
Last Posted Date
2021-09-28
Lead Sponsor
University of Cape Town
Target Recruit Count
52
Registration Number
NCT03927313
Locations
🇿🇦

Mitchells Plain Hospital, Cape Town, Western Cape, South Africa

🇿🇦

Livingstone Hospital, Port Elizabeth, Eastern Cape, South Africa

🇿🇦

New Somerset Hospital, Cape Town, Western Cape, South Africa

and more 1 locations

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

First Posted Date
2019-04-08
Last Posted Date
2024-12-06
Lead Sponsor
Yale University
Target Recruit Count
700
Registration Number
NCT03907046
Locations
🇺🇸

St. Jude Medical Center, Fullerton, California, United States

🇺🇸

Ascension Sacred Heart Pensacola, Pensacola, Florida, United States

🇺🇸

Javon Bea Hospital - Riverside, Rockford, Illinois, United States

and more 161 locations

Clinical Research on the Effect of Aspirin on the Disease Free Survival Rate of Esophageal Carcinoma

First Posted Date
2019-04-03
Last Posted Date
2019-04-03
Lead Sponsor
Hebei Medical University Fourth Hospital
Target Recruit Count
600
Registration Number
NCT03900871
Locations
🇨🇳

Junfeng Liu, Shijiazhuang, Hebei, China

INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE

First Posted Date
2019-03-12
Last Posted Date
2023-01-09
Lead Sponsor
Beijing Tiantan Hospital
Target Recruit Count
5438
Registration Number
NCT03871517
Locations
🇨🇳

Beijing Tian Tan Hospital, Capital Medical University, Beijing, Beijing, China

The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin

Phase 4
Completed
Conditions
Interventions
First Posted Date
2019-03-11
Last Posted Date
2023-04-13
Lead Sponsor
Sheffield Teaching Hospitals NHS Foundation Trust
Target Recruit Count
72
Registration Number
NCT03869268
Locations
🇬🇧

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath